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CONCLUSIONS: As well as resulting in cost savings, re-
classification will tend to improve equity of access to the
medicine. Given the potential for large cost savings to the
NHS and society we recommend that the status of POMs
be reviewed on a more frequent basis than the current in-
terval of five years.
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OBJECTIVES: To assess the degree of inadequacy of anti-
biotic utilisation and its associated costs in PHC centers in
Catalonia.
METHOD: We used an observational design. The uni-
verse of the study was all the visits due to infectious dis-
eases to PHC doctors of the 40 basic health care areas of
the Region “Costa de Ponent”. 2.500 visits were included
in the sample, corresponding to 29 centers and 251 pre-
scribers. The source of information was the clinical
records. The adequacy of the treatment prescribed was as-
sessed with reference to the recommendations of the Cata-
lan Society of Family Medicine, adjusted to the pattern of
antimicrobial resistance in the area. The efficiency of the
prescription was assessed taking as a reference the mini-
mum cost required by an adequate treatment that could be
achieved by using the cheapest alternatives.
RESULTS: The number of valid observations (visits due to
infectious diseases) was 2,470. In 1,349 cases (54.6%) an
antibiotic was prescribed. The treatment prescribed was ad-
equate in 56.3% of the cases. The treatment was assessed as
inadequate in 43.7% of the cases. In 92 cases an antibiotic
was required and not prescribed and in 680 cases an antibi-
otic was not required but prescribed and in the remaining
294 cases an antibiotic was required, but the antibiotic pre-
scribed was not the recommended one. The total cost of the
antibiotics prescribed was 3.5 million PTA. of which 2.4
million (68.7%) could apparently have been avoided. 1.9
million corresponded to clinically inadequate prescriptions
and the remaining 0.5 corresponded to clinically adequate
prescriptions that used brands of higher price than the low-
est priced alternatives available on the market.
CONCLUSIONS: Inadequate use of antibiotic causes un-
necessary costs to the health system and increases antibi-
otic resistance. Action should be taken to improve the ade-
quacy and efficiency of prescribing habits.
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OBJECTIVE: To investigate the incremental cost of
nosocomial pneumonia (NP) from the perspective of a
1,800 bed University hospital and health insurance funds
by means of matched pair analysis of patients with and
without NP (CDC criteria).
METHODS: Analyses were based on patient data gath-
ered between 2/97 and 3/99, a) prospectively in 5 ICUs
and b) retrospectively in 2 ICUs and the general wards to
which patients were transferred.
RESULTS: Prospectively, out of 114 patients, 29 pairs
could be matched. The incremental length of stay (LOS)
per NP-patient was 6.6 days (45%; 95% CI: 2.75–
10.43) resulting in total incremental cost of DM 14,606
per patient (95% CI: 5,285–23,927). Antibiotic cost was
DM500 higher (150%, 95% CI: 105–896), and cost
for microbiology DM486 higher (80%) for NP-patients
than for controls. From the health insurance fund per-
spective cost was DM7,988 (30%; 95% CI: 5,281–
10,694) higher. Retrospectively, out of 89 patients 37
pairs could be matched. LOS in ICU was 14 days longer
for NP-patients (80%; 95% CI: 11.2–16.9), the entire
LOS 10.1 days (190%; 95% CI: 6.6–13.7) respectively
which resulted in incremental cost of DM29,610 per pa-
tient from the hospital’s perspective (270%; 95% CI:
23,054–36,174) and DM18,000 (245%; 95% CI:
14,885–21,020) from health insurance fund perspective.
Incremental cost for antibiotics amounted to DM1,042
(870%; 95% CI: 718–1,367), cost for microbiology to
DM825 (384%).
CONCLUSION: The study not only gives insight into the
structure of incremental cost caused by NP but also
shows that based on a conservative cost calculation the
incremental cost per NP-patient is higher for the hospital
than for health insurance funds which indicates a signifi-
cant financial deficit for the hospital. Antibiotics and mi-
crobiology together only contribute 6.8% to incremental
cost. Therefore in a cost saving initiative their close rela-
tionship to LOS must be considered.
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OBJECTIVES: To measure cost-effectiveness of the two
most commonly used inhaled corticosteroids in asthma: Pul-
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micort Turbuhaler® (budesonide) and Flixotide Diskhaler®
(fluticasone propionate).
METHODS: A prospective health economics analysis was
conducted in an 8-week, open, randomised, parallel-group
trial comparing three treatment strategies: budesonide dry-
powder inhaler 400 g/day (BUD400), fluticasone propi-
onate dry-powder inhaler 400 g/day (FP400) and budes-
onide dry-powder inhaler 1600 g/day (BUD1600). 557
patients from Switzerland (CH), the Netherlands (NL) and
Italy (I) participated. Health care costs and effectiveness
were analysed in a cost-minimisation analysis with a third-
party payer perspective. Effectiveness was measured as
symptom-free days (SFD). Pooled resource consumption
was analysed with the three countries’ prices in one analysis
each. The health economics analysis included BUD400 and
FP400, while the BUD1600 alternative was viewed as a ref-
erence arm in the clinical study.
RESULTS: The percentage of SFD was 54.1 for BUD400
and 58.9 for FP400 (NS). The 8-week health care costs per
patient were 60 (CH, p  0.01), 38 (NL, p  0.01), and 49
(I, p  0.01) percent lower for BUD400 than for FP400. Re-
calculated to US Dollars, this is equivalent to a lower 8-
week health care cost of USD 142.53 (CH), USD 30.31
(NL), and USD 45.11 (I), respectively for the BUD400 treat-
ment.
CONCLUSIONS: Budesonide was a more cost-effective
treatment alternative than fluticasone, since the cost was
significantly lower for the budesonide treatment in all 3
countries studied, with no significant difference in effect.
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OBJECTIVES: Acute tonsillopharyngitis (AT) is caused
by Group A beta-hemolytic streptococci (GAS) in fewer
than 30% of children. There is a risk-benefit tradeoff
when considering whether to test and/or treat. On the
one hand cost of testing (throat culture and express-tech-
nique) is comparatively higher than cost of antibacterial
treatment; on the other hand overtreatment promotes
drug resistance and may produce unnecessary adverse re-
actions.
METHODS: Three strategies were considered: 1) Treat all
patients with penicillin V, 10 days (RxALL); 2) Use ex-
press-test to detect GAS and treat patients with positive re-
sults (ET/Rx); 3) Culture to detect GAS and treat pa-
tients with positive results (C/Rx). Baseline estimated
values for variables included the probability of positive
culture in children with clinical symptoms indicating the
GAS etiology (0.4—our own data), sensitivity of express-
test (0.65)—Directigen, Becton Dickinson, USA (available
in Russia) and sensitivity of culture (0.9). Finally for each
strategy a cost/effectiveness ratio (C/E) was calculated,
where C was costs of tests, cultures and Rx from the per-
spective of a second–party payer; E was Correct Treatment
Decision (culture positive patients who were treated and
culture negative patients who were not treated). Decision
analysis was done with DPL software (ADA Inc). Sensitiv-
ity analyses were applied to analyze the impact of varying
the probability estimates and cost variables.
RESULTS: C/Rx was the most cost-effective strategy
(C/E  229), followed by RxALL (C/E  248) and ET/
Rx (C/E  786). Sensitivity analysis comparing C/Rx
to RxALL showed that C/Rx was sensitive to changes
in several variables. Specifically, RxALL was preferred if:
The cost of Rx decreased (	0.9); cost of culture in-
creased (
2.02); sensitivity of culture decreased (	0.59).
CONCLUSIONS: C/Rx is the preferred strategy in the
decision-making process for antibiotic treatment of acute
tonsillopharyngitis in Russian children.
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OBJECTIVES: To determine the health and economic
burden on health care systems of smoking-related illness.
Additionally, to demonstrate the disease cases and costs
averted with successful smoking cessation programmes.
METHODS: A number of different modelling techniques
were considered. Discrete difference equations were cho-
sen as the most appropriate for modelling smoking status
and health changes, as well as key smoking-related dis-
ease costs and the effects of smoking cessation products,
within six European countries. A user-friendly interface
was constructed using Visual Basic with an Access data-
base. The study was performed as part of the WHO Eu-
ropean Partnership Project to Reduce Tobacco Depen-
dence and the countries thus included the four of the
WHO Partnership Project (the UK, France, Germany, Po-
land) and additionally the Netherlands and Italy. Within
each of these countries, six smoking-related diseases were
considered, COPD, asthma exacerbations, stroke, heart
disease, lung cancer and low birth weight. From current
smoking prevalence, disease prevalence and incidence,
and local treatment patterns and costs of these smoking-
related diseases, the model predicts disease outcomes
(e.g., number of cases) and costs in the short term (2-, 5-
years) and in the longer term (10-, 20-years). Assuming a
one-off investment in smoking cessation products, the
model also considers the improved outcomes that might
be seen from such a cessation program.
RESULTS: The model demonstrates that over the next
20 years in these European countries, between 33% and
54% of current smokers will contract a smoking-related
disease, resulting in 14 million preventable deaths. If the
prevalence of smoking remains constant, more than US
